Arosenius lectures

2025

Christopher Ludlam

EAHAD – Paths to Progress

EAHAD i Milan

2024
Karin Fijnvandraat
Insights intonon-severe hemophilia

EAHAD i Frankfurt 

2023

Glenn Pierce 
What is the future landscape for treatment of inherited bleeding disorders
EAHAD i Manchester UK

2022

Rolf Ljung

What is the "true" rate of  inhibitor development in Haemophilia?
EAHAD virtuellt möte

2021 

Marilyn Manco-Johnson
Prophylaxis in haemophilia
Held at EAHAD, Virtual Congress

2020

Brian O´Mahony
Hemophilia Care in Europe
Held in EAHAD Amsterdam

Steven Pipe, MD
Gene therapy
Held at WFH 2020, Virtual Congress

2019

Prof. Philippe De Moerloose,
Haemophilia in Africa
Held att EAHAD 2019, Prague

2018
Evelien Mause-Bunschoten
Ageing and haemophilia
Held att EAHAD 2018, Madrid, spain

Amy Shapiro
Optimizing bleed prevention: womb to tomb.
Held at WFH 2019, Glasgow, Irland

2017

Jenny Goudemand

Importance of phenotypic and genotypic characterization for treatment  of Von Willebrand Disease: lessons from the French cohor

Held at  EAHAD 2017 Paris, France

2016

Professor Erik Berntorp, Sverige

“The use of prophylaxis in vWD – remaining issues”

Held at the EAHAD congress in Malmö

Professor Midori Shima, Japan

 “Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A”

Held at the WFH congress in Orlando

2015

Professor Riitta Lassila, Finland

”Platelet procoagulant activity”

Held at the EAHAD meeting in february in Helsinki

1997

Dr Mark Kay,

University of Washington, Seattle, USA

Held in Stockholm

1998

Dr Inder Verma

The Salk Institute, La Jolla, USA

Held at the WFH congress in The Hague

1999

Professor Christine A Lee

The Royal Free Hospital, London, UK

Held in Stockholm

2000

Dr Katerine A. High,

Children´s Hospital of Philadelphia, USA

Held at Gene Therapy Congress in Stockholm

2001

Dr Paul Giangrande,

Oxford Hemophilia Centre, UK

Held at the EHC congress in Malmö

2002

Professor Stefan Karlsson, Department of Molecular Medicine and Gene Therapy Lund, Sweden

”Development of Gene Therapy for Blood Disorders by Gene Transfer into Hematopoietic Stem Cells”.

Held at the WFH Congress in Seville

2003

Professor Mammen Chandy

Christian Medical College Hospital, Vellore, India

“Ethical Dilemmas in Hemophilia Treatment in Development Countries“

Held at the Arosenius symposium in Helsinki

2004

Professor Ian Peake

University of Sheffield, UK

”Genotype/Phenotype Correlation in von Willebrand Desease and its Impact on von Willebrand Nomenclature”

Held at the WFH congress in Bangkok

2005

Professor Victor Blanchette

Hospital for Sick Children, Toronto, Canada

“Towards Optimization of Factor Prophylaxis in Hemophilia”

Held at the Arosenius symposium in St Petersburg

2006

Professor David Lillicrap

Queens University, Kingston, Canada

”Hemophilia Gene Transfer: Past Lessons and Current Obstacles”

Held at the WFH congress in Vancouver

2007

Professor Wolfgang Schramm

Ludwig-Maximilians-Universität, München, Germany

“Hemophilia in Europe with Respect to Clinical Outcome, Quality of Life and Care Resources”

Held at the Arosenius symposium in Stockholm

2008

Professor Donna M. DiMichele

Cornell Medical College, New York, USA

“Aspects on Surgial Procedures in Early Infancy”

Held at the WFH congress in Istanbul

2009

Professor Johannes Oldenburg

University Clinic, Bonn, Germany

 “Anti-factor VIII antibodies – who, why and can it be prevented?”

 Held at the Arosenius symposium in Malmö

2010

Professor Pier Manucci

A. Bianchi Bonomi Hemophilia Center, Milano, Italien

“Treatment of Von Willebrand Disease”

Held at the EAHAD congress in Edinburgh

MD Katherine A. High, University of Pennsylvania School of Medicine and Howard Hughes Medical Institute, Philadelphia, USA

”Gene Therapy and Inhibitor Development; The Final Solution?”

Held at the WFH congress in Buenos Aires

2011

Professor. E. C. Rodriguez-Merchan Department of Orthopaedic Surgery, La Paz University Hospital, Madrid, Spain

“Haemophilic arthropathy - Aspects of Current Management: Orthopaedic Surgery in Haemophilia”

Held at the EAHAD congress in Geneva

2012

Professor Edward G. D. Tuddenham,

University College London, UK

“Gene theraphy trial in severe hemophilia B”

Held at the EAHAD congress in Rome and published in Hemophilia Volume 18, issue 1, January 2012

Professor Erik Berntorp, Department for Coagulation Disorders, Malmö University Hospital, Malmö, Sweden

“History of Prophylaxis”

Held at the WFH congress in Paris

2013

Professor Sven Björkman, Uppsala University, Uppsala, Sweden

"Pharmacokinetics of plasma-derived and recombinant factor IX"

Held at the EAHAD congress in Warsaw and published in Hemophilia Volume 19, issue 1, November 2013

2014

Professor Johannes Oldenburg

University Clinic, Bonn, Germany

 “Anti-factor VIII antibodies – who, why and can it be prevented?”

Held at the EAHAD meeting in february in Brussels

Professor Alok Srivastava, Department of Haematology, Christian Medical College, Vellore, India

 “Defining care in haemophilia: beyond the treatment guidelines”

Held at the WFH congress in Melbourne